Insider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) Director Sells 15,040 Shares of Stock

TransMedics Group, Inc. (NASDAQ:TMDX) Director James R. Tobin sold 15,040 shares of the company’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $106.43, for a total transaction of $1,600,707.20. Following the transaction, the director now owns 205,171 shares of the company’s stock, valued at approximately $21,836,349.53. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

TransMedics Group Price Performance

NASDAQ:TMDX traded up $3.55 during trading hours on Friday, reaching $127.99. The company had a trading volume of 1,543,089 shares, compared to its average volume of 765,449. The firm has a market capitalization of $4.19 billion, a PE ratio of -376.44 and a beta of 1.87. The stock has a 50-day moving average of $85.54 and a two-hundred day moving average of $76.85. TransMedics Group, Inc. has a one year low of $36.42 and a one year high of $129.66. The company has a quick ratio of 8.49, a current ratio of 9.30 and a debt-to-equity ratio of 3.69.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.40. The firm had revenue of $96.90 million during the quarter, compared to analysts’ expectations of $83.78 million. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 8.29%. TransMedics Group’s revenue was up 132.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.08) EPS. Analysts forecast that TransMedics Group, Inc. will post -0.14 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have commented on the stock. JPMorgan Chase & Co. upped their target price on shares of TransMedics Group from $105.00 to $127.00 and gave the stock an “overweight” rating in a research report on Wednesday. Canaccord Genuity Group boosted their price target on TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a research report on Wednesday. TD Cowen upped their target price on TransMedics Group from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday. Morgan Stanley raised their price objective on shares of TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 28th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $120.00 target price (up from $95.00) on shares of TransMedics Group in a report on Wednesday. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $119.00.

Hedge Funds Weigh In On TransMedics Group

A number of hedge funds and other institutional investors have recently made changes to their positions in TMDX. Venturi Wealth Management LLC bought a new position in shares of TransMedics Group during the 1st quarter valued at about $30,000. Fidelis Capital Partners LLC bought a new stake in TransMedics Group in the 1st quarter valued at approximately $35,000. Cutler Group LLC CA boosted its position in TransMedics Group by 600.0% during the 3rd quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock worth $38,000 after acquiring an additional 600 shares during the last quarter. RiverPark Advisors LLC bought a new position in shares of TransMedics Group during the 3rd quarter worth approximately $60,000. Finally, First Horizon Advisors Inc. raised its holdings in shares of TransMedics Group by 26.8% in the fourth quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock valued at $83,000 after purchasing an additional 222 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.